Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Total Current Liabilities (2018 - 2025)

BioNexus Gene Lab's Total Current Liabilities history spans 8 years, with the latest figure at $678023.0 for Q3 2025.

  • For Q3 2025, Total Current Liabilities fell 52.08% year-over-year to $678023.0; the TTM value through Sep 2025 reached $678023.0, down 52.08%, while the annual FY2024 figure was $2.0 million, 19.64% up from the prior year.
  • Total Current Liabilities for Q3 2025 was $678023.0 at BioNexus Gene Lab, down from $1.8 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $3.0 million in Q1 2021 and bottomed at $678023.0 in Q3 2025.
  • The 5-year median for Total Current Liabilities is $1.7 million (2024), against an average of $1.8 million.
  • The largest annual shift saw Total Current Liabilities skyrocketed 6882.74% in 2021 before it tumbled 52.08% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $2.3 million in 2021, then dropped by 13.94% to $2.0 million in 2022, then fell by 18.62% to $1.6 million in 2023, then rose by 19.64% to $2.0 million in 2024, then tumbled by 65.25% to $678023.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Total Current Liabilities are $678023.0 (Q3 2025), $1.8 million (Q2 2025), and $1.6 million (Q1 2025).